Equity Overview
Price & Market Data
Price: $0.671
Daily Change: -$0.014 / 2.09%
Daily Range: $0.671 - $0.705
Market Cap: $5,210,506
Daily Volume: 45,204
Performance Metrics
1 Week: -3.46%
1 Month: 0.16%
3 Months: -38.05%
6 Months: -74.45%
1 Year: -88.80%
YTD: -77.78%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.